Tonix Pharmaceuticals Holding Stock Fundamentals
| TNXP Stock | USD 0.19 0.01 5.00% |
Tonix Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Tonix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tonix Stock. The fundamental analysis module provides a way to measure Tonix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tonix Pharmaceuticals stock.
At this time, Tonix Pharmaceuticals' Total Other Income Expense Net is relatively stable compared to the past year. As of 11/27/2024, Non Operating Income Net Other is likely to grow to about 30.2 K, though EBITDA is likely to grow to (108.4 M). Tonix | Select Account or Indicator |
Tonix Pharmaceuticals Holding Company Return On Equity Analysis
Tonix Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Tonix Pharmaceuticals Return On Equity | -1.63 |
Most of Tonix Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tonix Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Tonix Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Tonix Pharmaceuticals Holding has a Return On Equity of -1.6324. This is 93.19% lower than that of the Biotechnology sector and 95.52% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Tonix Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tonix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tonix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tonix Pharmaceuticals competition to find correlations between indicators driving Tonix Pharmaceuticals's intrinsic value. More Info.Tonix Pharmaceuticals Holding is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tonix Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tonix Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tonix Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tonix Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tonix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tonix Pharmaceuticals by comparing valuation metrics of similar companies.Tonix Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Tonix Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (8.31) % | ||||
| Current Valuation | 15.74 M | ||||
| Shares Outstanding | 186.89 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 7.67 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 2.83 X | ||||
| Revenue | 7.77 M | ||||
| EBITDA | (114.09 M) | ||||
| Net Income | (116.66 M) | ||||
| Cash And Equivalents | 145.48 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 9.81 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.05 X | ||||
| Book Value Per Share | 57.61 X | ||||
| Cash Flow From Operations | (102 M) | ||||
| Short Ratio | 0.35 X | ||||
| Earnings Per Share | (80.39) X | ||||
| Target Price | 21.0 | ||||
| Number Of Employees | 103 | ||||
| Beta | 2.08 | ||||
| Market Capitalization | 35.29 M | ||||
| Total Asset | 154.46 M | ||||
| Retained Earnings | (600.66 M) | ||||
| Working Capital | 28.88 M | ||||
| Current Asset | 46.36 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 154.46 M |
About Tonix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tonix Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tonix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3 M | 1.7 M | |
| Cost Of Revenue | 4.7 M | 4.5 M | |
| Total Revenue | 7.8 M | 8.2 M | |
| Stock Based Compensation To Revenue | 1.07 | 0.95 | |
| Sales General And Administrative To Revenue | 4.03 | 3.58 | |
| Research And Ddevelopement To Revenue | 10.04 | 8.93 | |
| Capex To Revenue | 0.91 | 0.82 | |
| Revenue Per Share | 13.13 | 11.67 | |
| Ebit Per Revenue | (13.72) | (14.40) |
Pair Trading with Tonix Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Tonix Stock
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.